Actiofarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 10,282,935 | 13,871,052 | 12,975,121 | 14,857,049 | 19,944,084 | 22,161,900 | 25,006,735 | 32,885,143 |
| Profit before tax | 799,517 | 766,501 | 767,353 | 289,767 | 268,994 | 362,729 | 46,688 | 671,600 |
| Net profit | 678,799 | 631,850 | 632,738 | 239,422 | 246,467 | 302,792 | 31,904 | 551,062 |
| Equity | 1,302,701 | 1,784,550 | 1,617,289 | 1,856,711 | 2,103,178 | 2,205,970 | 1,661,874 | 2,212,936 |
| Liabilities | 594,188 | 954,330 | 328,731 | 744,514 | 1,275,746 | 781,222 | 1,681,888 | 1,294,162 |
| Non-current assets | 122,997 | 101,602 | 161,992 | 160,544 | 159,930 | 210,534 | 447,458 | 579,292 |
| Current assets | 1,773,892 | 2,605,115 | 1,828,816 | 2,439,660 | 3,210,008 | 2,769,680 | 2,889,899 | 2,895,774 |
| Total assets | 1,896,889 | 2,706,717 | 1,990,808 | 2,600,204 | 3,369,938 | 2,980,214 | 3,337,357 | 3,475,066 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 107,584 | 122,417 | 152,889 |
| Social insurance contributions | - | - | - | - | - | 526,905 | 631,853 | 724,806 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +5.4% | +34.9% | -6.5% | +14.5% | +34.2% | +11.1% | +12.8% | +31.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 35.8% | 23.3% | 31.8% | 9.2% | 7.3% | 10.2% | 1.0% | 15.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 52.1% | 35.4% | 39.1% | 12.9% | 11.7% | 13.7% | 1.9% | 24.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 6.6% | 4.6% | 4.9% | 1.6% | 1.2% | 1.4% | 0.1% | 1.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 7.8% | 5.5% | 5.9% | 2.0% | 1.3% | 1.6% | 0.2% | 2.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.5 | 0.5 | 0.2 | 0.4 | 0.6 | 0.4 | 1.0 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 313,983 | 336,268 | 301,747 | 288,954 | 312,848 | 275,019 | 279,405 | 312,695 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Actiofarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-06-11 | 2026-06-14 | 95.11 |
| 2026-06-08 | 2026-06-08 | 95.11 |
| 2024-01-23 | 2024-02-11 | 1.74 |
| 2023-12-18 | 2023-12-20 | 966.42 |
| 2023-11-16 | 2023-11-20 | 26.59 |
| 2023-10-30 | 2023-11-02 | 26.59 |
| 2023-10-25 | 2023-10-25 | 26.59 |
| 2023-07-26 | 2023-07-30 | 12.05 |
| 2023-07-24 | 2023-07-25 | 12.46 |
| 2023-07-18 | 2023-07-23 | 13099.62 |
| 2023-06-16 | 2023-06-18 | 0.01 |
| 2022-01-28 | 2022-02-01 | 44.48 |
| 2021-12-07 | 2021-12-08 | 0.01 |
| 2021-10-19 | 2021-10-19 | 29661.97 |
| 2021-10-18 | 2021-10-18 | 29529.13 |
Actiofarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Actiofarma, UAB (code 300121033) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €32.89M, up 31.5% year on year and 48.4% over two years. Net profit increased to €551.1K from €31.9K in 2024 and €302.8K in 2023, while the profit margin improved to 1.7% after a very weak 0.1% margin in 2024. The 2023–2025 revenue trend shows steady expansion, although profitability was uneven in the middle year before recovering in 2025. At year-end 2025, total assets stood at €3.48M, with equity of €2.21M and liabilities of €1.29M. The equity ratio was 63.7% and debt-to-equity 0.58, indicating a relatively solid balance sheet structure. Asset turnover reached 9.46x, reflecting efficient use of assets. Return on equity was 24.9% and return on assets 15.9%. Revenue per employee was €313.2K, while profit per employee was €5.2K.